← Oncology Approval Tracker

FDA DECISION ·

Xeloda + combination chemotherapy

capecitabine with combination chemotherapy · Genentech

FDA approvalNew or expanded indicationGastric, esophageal and gastroesophageal junction cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Part of combination chemotherapy for adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer.

LAMPGEN ANALYSIS

Why it matters

Project Renewal adds a broad upper gastrointestinal use for capecitabine as a combination component.

What research teams should watch

Record the primary site, resectability and partner drugs so the treatment is classified accurately.

PRIMARY RECORDS

Sources